<SEC-DOCUMENT>0001193125-14-401310.txt : 20141106
<SEC-HEADER>0001193125-14-401310.hdr.sgml : 20141106
<ACCEPTANCE-DATETIME>20141106171952
ACCESSION NUMBER:		0001193125-14-401310
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141106
FILED AS OF DATE:		20141106
DATE AS OF CHANGE:		20141106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		141201817

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d815969d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dated November 6, 2014 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name as Specified in its Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Translation of Registrant&#146;s Name) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Level 7, 151 Macquarie Street </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sydney, 2000 New South Wales, Australia
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form <FONT
STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If &#147;Yes&#148; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November 6, 2014 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prima BioMed Ltd</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Marc Voigt </FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marc Voigt </FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:75pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Exhibit</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CVAC Demonstrates Overall Survival Benefit in Second Remission Ovarian Cancer</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d815969dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g815969imag001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6&nbsp;November 2014 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVAC DEMONSTRATES
OVERALL SURVIVAL BENEFIT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN SECOND REMISSION OVARIAN CANCER </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Overall Survival data from the CAN-003 trial continues to show benefit for second remission ovarian cancer patients (&#147;second remission patients&#148;) using CVac </B></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Half of standard of care second remission patients survived past 25.53 months; more than half of CVac treated patients still alive after 36 months </B></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Data to be included in Poster presentation at SITC Annual Conference </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA - Prima BioMed
Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148; or the &#147;Company&#148;) is pleased to announce that CVac<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> has demonstrated a clinically meaningful improvement in Overall Survival
(&#147;OS&#148;) over standard of care (&#147;SOC&#148;) in second remission ovarian cancer patients in the CAN-003 protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In second remission
patients (n=20) from CAN-003, the median for SOC patients was 25.53 months, which is consistent with current literature. By comparison, for patients treated with CVac a median has still not yet been reached after 36 months (current hazard ratio=0.17
(95%CI: 0.02, 1.44); p=0.07). This implies at least a 10 month median survival advantage for second remission patients treated with CVac. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This means
second remission patients treated with CVac are living significantly longer and are 83% less likely to die compared with SOC patients. This follows the very positive Progression Free Survival (&#147;PFS&#148;) data for second remission patients from
CAN-003 announced in May 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For first remission patients, the interim data demonstrates a slightly positive trend in CVac patients with no median
reached yet in the CVac or SOC group. This confirms Prima&#146;s previous decision to focus further clinical development on second remission patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lucy Turnbull, Chair of Prima BioMed commented: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This
data is a strong confirmation that CVac could considerably extend the progression free period and the overall length of life in second remission patients with ovarian cancer. CVac has an excellent safety and tolerability profile that also supports a
potentially high quality of life given its very limited side effects.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc Voigt, Prima&#146;s Chief Executive Officer said: &#147;This data is
extremely encouraging and further supports the positive overall survival trend we presented earlier this year for second remission patients. Whilst we had anticipated the OS data for second remission patients to be mature enough for final analysis
by the end of this calendar year, given the better than expected results with the median for CVac patients still not yet reached, we will continue to monitor the second remission CAN-003 patients and look forward to updating the market on their
progress.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 7, 151 Macquarie Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim OS data from CAN-003 for second remission patients will be included in a poster presentation (Poster
Number P85) entitled &#147;Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1&#148; at the 29th Annual Meeting of the Society for
Immunotherapy of Cancer (&#147;SITC&#148;) on 8&nbsp;November 2014 by Prima&#146;s Chief Technical Officer, Sharron Gargosky. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the CAN-003
clinical trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAN-003 is a 63-patient phase 2 study evaluating the effects of CVac, as compared to an observational standard of care arm (SOC), in
epithelial ovarian cancer patients in complete remission after first or second line treatment. In accordance with the protocol design, the first seven patients on the trial were all assigned to receive CVac in order to test the comparability of
product manufacturing in a new facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The subsequent 56 patients were randomized 1:1 to either the CVac group or SOC and included in the
intent-to-treat analysis. 36 patients were in first remission (19 patients were assigned to CVac and 17 to SOC) and 20 patients were in second remission (10 patients were each assigned to CVac or SOC). Final PFS data was analysed after thorough
quality control reviews of investigator-evaluated progression and appropriate censoring of data from patients who had not progressed during the study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objectives of the trial were to determine the safety of CVac administration and to determine CVac&#146;s effect on progression-free survival.
Secondary objectives of the trial were to determine CVac&#146;s effect on overall survival and to evaluate host immunologic responses to CVac. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Prima BioMed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of
cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima&#146;s lead product is CVac&#153;, an autologous dendritic cell-based
product currently in clinical trials. <U>www.primabiomed.com.au</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>USA Investor/Media:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Australia Investor/Media:</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Adam Holdsworth, ProActive Capital</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Mr Matthew Gregorowski, Citadel</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">+1 (646)&nbsp;862 4607;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Communications</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">adamh@proactivecapital.com</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">+61 (0) 422 534 755;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">mgregorowski@citadelpr.com.au</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Europe Investor/Media:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Peggy Kropmanns, Dr.&nbsp;S&ouml;nke Knop, edicto GmbH</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+49 (0)&nbsp;69 905505-56,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">primabiomed@edicto.de</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>, Level 7, 151 Macquarie Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g815969imag001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g815969imag001.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`"$`L8#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4Z***@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBHC-@\CWZ]J=@):*C\X9IKW*H
M3D<`=?6D"UV)J*C67=C`_#/2I*`"BBBG8`HHHI`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%.P!1112`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBJ]Y,EK#)-*#LBC9FQZ`9H`\)_:8_:>7X/2Z3X5\!V$?B?XF>+
M91;Z#H0?@%N/.FQRL8Y/J<&NT\)6%Q\,_!$^H_$CQ`^H:FR_;-;U*8A8DDP-
MR1(.$B7HH].O-?G/^QOXT?\`:)_X*'^(?'7B=\R6-I?3:7`6^6*-"(8E`/3:
MA)X[DU]__M3>&]4\3?!;7K+P\LDMSMC<PQYS*BN"RCU.*FM4=.FY1U:1VY=A
M88G&4J$Y<L922;[)NU_D>8>(OV]_#.FWSP>']#U'6H58K]I,BPJWN`<DUV/P
ML_:E\)?&&\;0VCNM'U.Y0A+:Y<8F'?8X_B_6OSIE1X9GBE1XY8W(='7:RMW!
M'8UV_P`%?".M>,OB5H4'AF":6:TOXIIID)`MXE;+,S=N!C%?(4LZQDL0HRV;
M/Z`S?PRX>HY/*M&3A*,6^=R?Y/1W/J[5/V@KG]F'XP:9X%^,EX]QX%\4#/A3
MQ1<N7DM'7A[6[?\`BP2-K]<$9KZJM9S.@<,K*RAE(Z$'H:^-?^"I'ARSU+]E
M*\O+U$-UHFK6DUM*P^96+;&"GJ,@\_2NR_X)S_%+4_BI^S+H-YXFN9+W4](F
MFTN:>0Y:182/+8^IV,HSWVU]GOJ?SD?4%)FO@7_@K/\`$#Q3X!\)?#^?P)XB
MUGP]+>:G<1W#Z==M`95$8(#$=0#S7BWQ<\"?M"_LI_#_`$+XI^'_`(U:QXET
MB<6LEW9WT[D1M,@95:-R5=3RIZ&F!^LE(3CUK\H?VR/VJ/&'CO\`9U^"/CKP
MAK.K>$+WQ))?QZI%IEX\*O-#M5L$')7<"0.V:A^,OP>^/_P`^#NE_%?0/CQX
MAU:R\BUN;JTN;N2.2+SE4J%#$K*,L!MQG'K2L!^L@.?6EK\^/B;^T1XN^)/_
M``3/7XAK?WF@^*I9H+>>^T^0V[.\=SY;2*1T#`9QTY->W?L'^,M0UC]D#PQX
MA\::M>ZI>+!>S7E]?3F61UCGD)+,>3A12L!],9H'-?EW^P+^U9XC^(O[6_C#
M2O%FLZE?:-XR2\GTJQN;II(K%XI2Z)&IX4&/(X]*UOAG^UIJ^O?\%*M9T1-?
MU"[\%ZS<3Z):6#3DVT,D2821$S@,7C89]Z+`?I?29S4$MU%;6KR7,B1QPH6D
M9C@*`,DD_05^*/QE_:;^,'CSXD^,_B=X$\0:]8^!?"^O6]I'!9WTD=H$WD0J
M4!P2XC);_>HL!^VU%<?\(_'UI\4OAMX<\6Z4P-OK^FPW04'.QF7YU^H;(_"N
MPHL`A-&:_)SX[:E\1/B+_P`%"-2^&/A3XE>*?">G:M=QQ0_8[R3RK7%L')$8
M('4?K4>H^./C9^Q=^U'X5\'^(/B5>_$+3/$4EOOM;R9YA)!++L.8V):.4=00
M:+`?K/FEK\YOVW/B3XL\,?MI_"'1?#7B36M*TG419?;;"UO&CAN-UT00Z@X.
M5X->A_MX?M0^,OA[XB\,?"CX$1K_`,)UXXX%X#N>R1WV)L!X#,<G<?NA<T6`
M^UJ*_,GQQ^SO^U5\!/!1^(^D_&74/%&H:#";[6-$DN994\M.6"A_EE`&<C`X
MSBOL3]DC]H:/]I+X)Z?XPN8(K'4HI'M=6M87)2*>/[Q7/.T@AA]:+`>XYHS7
MY9?LM_M6^(O&_P"W]KEIXC\1ZE/X:\2W6H6.E:6]TQMH2G^I"(3@$B/.?4FN
MEUK]KS4;O_@I;I&@6NM7\/@O3;C_`(1R6R2<B"XN'1@TK)G!/FLH#>@HL!^E
M&<TM?G7_`,%5O'WB_P`'ZY\+;/P)XHUOPX-6FNH;EM-NWA\SYHPI;!&[&3Q6
MUI_[`?Q@<6EU)^TIXR=#LF:(B7!'!*_ZSI18#[Y!R**_.3_@JMX^\7>`9_AA
M;>!?%.N:!)J`N(KJ73[MH?.(,2AG`/)Y)K,\9?LJ_M/?"SPQ!XQ^%7QMU_Q9
M):6PO;G2[FYDC=T"[R$5RRR<?P\9J@/TOHKX^_8#_;+U#]IC0M8T7X@6UK9^
M,_#&QYVMQL6^@)*B78?NL&&&4<9(]:^P%.5!'0BIL`M%%%(`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`JM?1"XMY(7!*3(R/]""#5FFL@;KG\*`/PMT#6=7_`&#OVSKB
M7Q!:S7-OHFH3).BM@WNFW!)$BGN=I##W4U^U7@GQ_H/Q3\*V.N>!]3M=5TK4
MHA)#<P.'`Z$JV/NL.A!Y!KYU_;R_8V@_:8\(1ZCX46UM/'.@(3I]PZA?ML7>
MWD;T/52>A]C7YH?`']IGXD_L1_$"^TF_L+M--CN2NM^%M14Q*[]/,0D?(W'#
M#@XYR*I(32:LS]H==^`G@/Q/>-=Z]X7TFZNY#F27R=C.?4E<9K8\.>`?#O@.
MWDC\+Z38Z5'(`7^S1;=^/[QZFO-OA)^V)\-_B[\-KCQAI7B&QTRSTJ-3K,>H
MOY!T^3;N*,6X;C."N<XXKX2_;._X*:7/C6.[\'?L]7$^G:,Q\N^\2CY);Q<$
M%(5(RB'NW4]L5"I4U+F45<ZJF,Q-2E[*=23CV;=B7_@J5^U7IWC!K3X3^`;Z
MVU&ST^Z6Z\07D#AU,Z_ZN!6'#8R6;'?`KZV_X)O_``PU3X7_`+,6AV_B:UDL
MM2URYGU22"48>..4CRP1V)50V/\`:KXI_P""??[!UU\3]9L?B'\8]/EM_"-I
M-YVFZ9=Q%7UB3G$C#.1$K`'G[Q'I7Z[0VZ6ZJL0"HB[54#``K2YS'YT_\%EB
M?^$,^&V"/^0O=<'U\H5R\/[%W[3'[16@>'--^-GQ+TJT\"QVUM/;VMJXF(C"
M+Y>(E107"G&6/%?4G[</[(^J?M8:-X5L=#\0V&@'P]>RW,C75J\WF[U"@#:1
MC&*^B/"ND/H7A?2-+FD65].L(;9I%&`Y1`I(],XH`_+_`/X*B?#71_@[\(?@
MGX0\*1&+2M!>]AA#')D.R/=(Q[LS$D_6O)OVFOA;\3_A-X3^&^J_&7QCJ?Q&
M^'>K_9Y(]+%[+`D6(P_V<@=#Y>=K#T-?H+^W%^R#JO[6MAX0M=$\0V'A]O#M
MQ<RR-=6SS><)%0`#:1C&T]?6NS^-W[-=O\9OV=%^&FL75M'?6NGVL5AJ;Q$K
M;W,*JJRA0<X(##'H:`/#_P!L5_"\G_!-Y)?AE9PZ?X8GM=,ETRUBZ11-*AVD
M^N<Y)[YKS_PI\5)/A+_P27MM2L)`FHZG;W.EV1'!WW%S(A/X(7/X5ZW!^Q'X
MLD_8UOO@AK7C;3;VY:_673]5-I)Y=M;B59/**DY."&QSWK#\1?L`^*M>_9_^
M&OPJ;QMHZ:7X.U66_P!6D%A(?[1+2EU51GY<*[CGUH`^0?%^@2?L9S_L\?$C
M1=)(O=3\*S3:FC94W-PX<Y8]B(YX^/\`9J"3X?3_``%^$_P+^.4T$K:UK7C6
M74]4N)%P?L[.&B4_[)5';WW&OT<_:_\`V3[;]IKX9:%X8LK^VT2]\/W\4]G>
M26YE6.)5V21A01]Y<8]P*N?M&_LMVWQO_9UB^&&C7MMI+::MF--O)H3(D!@`
M7)0'/*[A^-`'/?MY_'ZS^%G[,.IZAI<V^_\`&]N-/T;RWP3Y\>6<8[",L<^N
M*^#_`(*?&WX:>#/V0?$WPM\9>%?&VH:UXJ-S=37=KHQ>*.X(`MF5NIV;5.?K
M7UQ\9OV$O%_QNC^%ND>*?'&E#PQX`TVVM;RP2RD+7TJ[1-(&S\I9$51GI7V3
M9>'=-TBP@M;"QM(H+:)(HD\E<*J@!1T]`*`/@#_@D5\:EO?!OB+X9>(+^1M2
MT2Y^WZ3:S9WBV?B5%SV5QG';>:_10'-?%OAW]A76/`'[7UQ\8/`7BK3+/1KZ
M]EGO-#ELWWM'.N)HPX.`-V&''6OLZW),(SUYH`_(+XY>!+WXE?\`!3Z\\-:)
MXBU'PI?:K>1+%K&GY\^T(M,Y7!'7&.HZU>^)?@.^_8,_:+\(^)?B%<:=\8+7
MQ(Z>5J?B`.U_8NCJ&D1=[890P*DY'6OH/XU?\$_?'7Q`_:.U/XL?#OXD:?X1
MU"XFCDL6%C(\]J5B$9.X''//;O5/0/\`@F=XA\4_$G2?%_[2'Q5O?'TFDRI(
MEK]F8><J-N6-G=CA,]0HH`\Y_;IG2Z_;D^!L\.3'/'I\B$C!*M=9&??FMWXU
MN/#7_!6+P!J?BJ1(-,U"RM4L)YSM0-Y4L8`/KYAQ]37M_P"T+^QEJOQG_:"\
M!_$33/$FGZ98^#!;B33Y;1W><13>9A6!P../PK=_;%_9`T_]J'2-+OM,U-O#
MWC/PVYDT?554LHY#>7(!R!N`8,.010![7\4-=T[1OAIXHO\`6IHH-/MM'NGG
MDFX55\I@<U^9O[(/CC4OA!^P+\;?&5J6MENM0>#16;@><\:Q?+[C>/RKO-2_
M9._:[^+-E_PAGQA^*>DIX*EQ%>S02K+)=1`YP56-6<\#ACBO9/C!^PO_`,)7
M^SCX:^#_`,*M>M_#.CZ+J,=WJ$]Y`\S:B0#N+;2.6<[O3@"@#X%N_A-JW[,/
MPR^`WQR%N\NJ7&JS76H0L=I=7;S+;)ZY,8;\ZMI\,=2TC]FRT_:)\26QBUZ]
M^)4.JQ3,OSO9%SDCT4R9(^@K](_VD_V5H_CM^SUI_P`-=-U2WT>71S9&QO9+
M<NL7D*$/R@YP5S5OXI?LM6WCS]E-/@YHVH1:>MKI=I:6M]+"75)(&5MY4'/S
M%3_WU0!\<?\`!5G6(/&T?P/U/1K@"UUR&6>UN8SG:LODE6!_']*]R\`_L,_$
M/PYX@\/:W?\`[1/CK5+#3[B"ZETN='$=RBD,8F_>GY2!MZ=#6-\7O^">7BKX
MI?"SX2^%8?'.DV&H_#.QDMGOGLI'%SEE\LH,Y7`4=:EM_P!D+]IRU>)'_:5N
M'MXMNZ(6DGS("/EZ\9`Q0!YM_P`%ACG6?A'TYGN?_0XJ_0>;Q/I7@_X?6^L>
M)[N&QTS3M,CGN;B=PJ1HL0)))[^U?.?[:?[&FN?M5#P4VB^*-.T"3PNL@>2Y
MM7F,S.$P1@C&"E>7>(_^"=/Q=^*%C;Z/\8_V@=1UG0+=E*6,%E(5`7@?*6"D
M@=,@T`>=_P#!,]H_&'[7'Q9\7>&;26+PY=07;PR;-JHL]V'B3'J5&<>U?J:O
MW1]*\I_9U_9P\'_LW>"O[!^']J^ZX=9-1U"=MT]_*!C?(>@XX`'`KU>DP"BB
MBI`****`/E_1OVZ_!MVRC5]-U[3??8LP_P#'379:?^UU\,M1QG7Y;8D=+BT=
M?Z5^<XSVYIW7J.E?%QXAQ5KV1_0E;PKR::]R4H_-/\S].;#]H/X>W[*+?Q?H
MX9NBR3[/YUUFG^-]#U5`VFZUI-T#T\J\0Y_6OR:VJ>P_&I(&:!]T#O&?5&*G
M\Q6U/B2K]J"/(K>$]!_PL4UZI/\`(_75+R.;`C=&ST*MFGEB1R?UQ7Y+QZ[J
M2`!-3U-0.@6[D`_G5[3O&VOZ5/YMCK.I(<\YN6;/X$FNF/$L+V=,\Z?A'B+.
MV*3]8M?D?JT"2!AN*49!R6&*_-C2/VDOB-HRA;+Q'*8UZ++!&XQ^5=39?MD?
M$>U(-Q/I5T!U#V>,_D:ZH\1X5[IH\BOX89U3^%PDO7_,_0`-N_B%-.=_48^M
M?$-G^W)XNB*_;-#T.X`ZX:1"?R-=1IG[=<9(_M;PM-&>YMKL,/P#"MXYY@I;
MR/*K\`9_2U]@GZ-,^N2W(Q4E?-^G?MN>#+C;]NTW78'XSB)'`_)JW[/]L?X<
M73A9+S4K?/>6Q;`_$9K>.8X5[31YM3A?.*:N\-+Y*_Y7/<:*\WTO]HKX=ZLJ
MFV\4:>A;^&8F,_J*W[7XH>$[['V/Q#I$V>FV[3_&NB->E+:2/,JX#%TOXE*2
M]8O_`".IHK.M_$&G73;;:]M)3_L3*?ZU<6X1S\AW>X.:T4HO9G,X26Z):*B^
MT#)X(QZB@W"@`\\U2U(NB6BH$NU=MH!!QGFI/,7U%%F--/8?13=XQFFF9119
M@245%YZ^AI1,O?(HLQ73V)**9YJYX-!D'N:+#'T4P2@BCS,G@&@5Q]%)FEI#
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`$*@]0/RKY=_;9_9B^&GQC^'^J^)OB3<#PUJ7ARP>6+Q1#'NDMHE^8JZ#
M_6KG@*>>>*^HZ^-O^"J$VMI^RM>CP^)1;G6;3^U&3^&WW'J?[N_;^E`'Y+_%
M'XE1>(X[7P[X/M/[$\$:*Y_L[3X\J;ER`K75P?XYGQDYX7.T=*^LO^"8W[-'
MPZ^,NH:QXC\?7']LZQX8N8Q;>')5V1(#RER_.9!D$;>@(YZU]5?L1_L<>%?"
MW[-H_P"$TLK?6=3^(^FK/JDLL8)MH)4_=Q1$C*E5.<CG<?:OG_\`8O\`A->_
M`W_@H=XM\$Z=-<7.E:1I5V#*QR7MF"/`7(XSDJ/<CWJP/U/M[>.W@CCAC2-(
MU`554`*!TP.U34B_=&.F*6I8"4M%%-`)M'H/RH(!ZTM%,!-H'8?E1@>@I:*`
M$P/04;1Z#\J6B@!-H]!01GKS2T4`-V+G.!GZ4H&!Q2T4`)@#L*,4M%`"8HVC
M/0?E2T4`)@4;1C&!^5+10`F!Z"@`#H!S2T4`)@#H.M&!Z"EHH`3`]!2T44`(
M!CI2T44F`4445(!1110!^<=U^Q[\3[7+1Z38W`'_`#QOT)_7%<CKOP,^('AP
M$ZOX4U8`'&Z"'S@?Q7-?J3M'H.*0QJ>H%?//AO#?9DS]-P_BGF\/XL(2^]/\
MW^1^1-SHNI6;LM[IVH6Q4\K+:NI'YBJG*G!^7!P0>M?KU/IUK=?\?5M!-_UT
MC#?S%8.J_#3PIK*D:GX<T6YW9SYEDG^%<\^&4]IGM4/%Q_\`+W"KY2O^:/RG
M5L'VJ3^M?I+JO[-'PXU13YOA/38B>]N&B/\`XZ:X[6_V+/`&I'=IZZMI3D<&
M&Y+J/P:N*?#>(C\#N>K0\4\KJ.U6G-?)/]3X,6G9)K[!O_V#-/9F.E^*K],]
M!/:*<?B"*Y?5_P!ACQ';9_L?7-,NR/NB:-HOU&:YIY'C8_8/7H^(.05]%6MZ
MIH^:ATIZ8/!KV*__`&1OB58,0FE6=VH_B@O5.?P/-<W>_`7X@Z46^U>$M5..
M<Q)O!_*N66"Q--ZP9Z]'B3*:W\/$1?S1PW0>GTIR$+PH`'M5_4/#NK:3*5U7
M2]1LR.HGMG7'YBJ`!0DR!DQ_>&*Y9PE'XDST(8C#U=8M/T:9/LW@<<^M2(H7
MD#!/6HU;CCD'TJ1#Z\?6G%V6FA;4)?$]/7]"Q%/+$P:*61&]5<BM>U\9:_8L
M/L>MZM"!T"7C@?EFL13G!'(J0</FJ56I%7C+\3FK87#S^*"EZV_R.PM/BOXS
MM2/(\4:TH'_3R3_.N@T[]H?XA:<04\1W,ZCC$\2./Y5YHIXJ<#`%;+%XB.O.
MSSJN3X"JK3HP:]$>VZ?^UIXULQ^_32KDGC,EL5)_(UMP?MB^(P,7&B:1*P[A
MW7^M?/*GFIAG/%;QSC&QVFSRJ_!^237^[17HO^"?3&G_`+9UXH7^TO#4!`^\
M8+H_U%=-IW[87AZ;']HZ1JELQZ^7MD`_6OD:/C.*F7[F.U;PS[&K=GE5N`\E
MEM!Q]&_U/LZW_:M\%3_?;4X?]^V_P-:=M^TIX"N`/,U1X2?^>ELX_I7Q%'T&
M*GR3ZFMX\1XI;I,X)^'>5OX9R7S7^1]WV/QJ\%:B1]C\0:?DG^-]O\ZZ"U\9
M:/>`&UU739%(X(N4Y_6OSU7&,GDU*@P1Z^M=,>):KW@CS*GAQA[^Y7:^29^B
M"ZQ:R_ZNZLW],3*?ZU*EXCD!7C.?0YK\\XII5(V22K]'(K2M-;U*T/\`HNH7
ML1'39.PQ^M=,>(XVUIG#5\.9KX,1_P"2_P#!/T#`)[XIZ\9S7PC:_$+Q-;$>
M5K^JJ!ZW+'^M:EO\7/&,!_=^(M1_%PW\Q51XBH/[+..7A]C%M4C\[H^W*0'-
M?'%I\<?&UL`3K;RGTEA1OZ5NV?[1OBZ,CS&TV<#^];XS^1K=9]A7W..IP/F<
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M/DZ6]P-LD<*YV1N1U"C"[NI`&>:S_AO\%]%\":[XH\2Q[KWQ/XSO1<ZQJ4H^
M9PH"QPI_=B0`87ZD\UWY.?O#\UI58*,*`!^55N)21*!@`>E+47F?YS1O/JO_
M`'U18=R6BHMY]1^='F>X_.FD*Y+147F>X_.CS/<?G3L%WV):*B\SW'YTGF^X
M_.DQW9-14/F'U'YTGF'U'YT!=D]%0;R?XC09&`XRWM2;#F1/15?S&/\`"P_&
M@2MTPQ-3S?U<+EBBJXD8GH1]33MQ[M5*["Y-15<[V/RR8_6C]X#]\'\*JP7+
M%%0>:W>E$I[8/U.*5F":9-14/F,?3\Z:LV/O-Q[B@+HL454DO;>/_67$2#_:
MD`JI-XATN#_6ZE8H/]JY4?UJ/:1[EQA.6R-:BN.U+XK>$-)5FU'Q/HMOMZAK
MY,_EFN4U']J7X9::VV;Q=8.WI$KR?R%9RQ5".\T==/+,=4?N49/Y/_(]<HKP
MBZ_;*^&5H3LUJ[N?^N-E(W]*YC5_V[_!=F7&EZ=KFH$'Y<(L0/\`WT:PGF.%
MCO-'HT>%\YK.T,+/[CZ>HKXOU'_@H/+N*Z3X-<#^%KB_ZCZ!:YS4?V^/&,Y/
M]FZ)HEJ.V\O(1^HKFEG.#BOC/8I>'G$,VDZ'+ZM+]3[R+`'FBOS7UG]L/XHZ
MI.9(]<MK!,\1VMHJ@?GDT5ROB+")]3U(^%>=M7<H+_M[_@'Z4T445[Q^:A2<
MYYZ4M%`#&4X^7&:;L8]2*EHIO45B+RCGG^=$D18<`?G4M%%PL1+$0.:##D]:
MEHHNP:3W*<NGQS`B:*&0'J&0'^=9=[X$T+4B1J&CZ5.K#G?:(3_*N@HJ'"#W
M2-(5:D'>,FO1V/-]2_9Z\`:I*7NO"VF$GJ44H?T-8=_^R?\`#N]4^5I$MJYZ
M-#=R#'X9KV2BL)X/#SW@CT*.=9E1_AUYK_MY_P"9\U7_`.Q#X?F!.G:_JUJV
M<J'590/;M7/7_P"P_=*W_$N\40G/_/>T.?T-?6U(<=ZYIY1@YOX#U:7&N?4E
M:.(?W+_(^)M6_8X\8V`)TZ]TB_"]`)&B/ZBN6N?V<OB):9#>'Y)\'K#.C?UK
M[_9<GUJ$Q@'C(KGGP_@WM='I4?$;.(:2Y9>J_P`C\[KOX0^-=.R;OPSJR*O5
MA!N'Z5A7.D7UDS+?65[;E>OF6[+C\Q7Z7&/)&<\>HJ*XL;>X!%S#!*".CQAO
MYUR3X:IOX9GJ4O$_$+^)0B_FT?F?&R]C^?%3IRN,C/IFOT/N?`'A[4"3>:+I
M\P;^]:IC^59%_P#`OP+J$967PWIRD]XT*?R-<T^&*OV9H]"GXEX:3_>X>2]&
MF?!<7&<U/&1@C()]J^T+G]F'P'<9V:?<6Q/_`#QN6'\\UA:C^R1X7G#?V??Z
MO:GL2ZR#\<BN:7#N*CM9G=3\0LJGNI1]5?\`(^3P.:G4]*^AKO\`9`D!8Z?X
ME&,<+-:?U!K*NOV3M?AXM-7TV<]@RLI-8/)\9%?`=U/C')JG_+ZWJFCQ:,XJ
M56&?K7HNH_L[>-=.)$5E;78'>&X&?R-8T_PC\8V@S/X?OL#N@#Y_(UC+!8F.
MC@SNCGV65%[M:/WG,1#@U.G\JOS>$-<LL_:=(U*+'4M;-C^549(9;5ML\<L1
M[[T*_P`ZR]A4BOA?W'5#$T9Q]V::\FG^3)0>!5A.F?6JB8<91UQZ@YJ>-\XP
M0?H:E7Z@VUK?^OQ+*-@\5.C<\U60583[U-&32;N68V'`J>-AOQ[540Y_"IXV
MZ5HHKL935V7%'-2J=IJO&_8U(9*T3L9RII:Q+<;]`:D)]*IH_`([T\.35IKJ
M1RNQ8.#UX-)O/8E2.AS4.^F[^:KG\R/8I[HE-Q(IRDTH)/57(ICZC>(PV7=T
M![3L/ZU`7&3]:9)(,YJ/:S6S'+#T[?"ON19_X2#4X#^[U&_4CIMN7_QJ0>-_
M$,./*UK4E'<?:":RG?YOK5>0]J3Q%9;38HX.A+XH+[D="/B7XIA'[K7=1'UE
MS2_\+9\7(,KKMYGWP?Z5RTDF,#UJ%CNIK%XCI4?WB>58%ZNC'[D=F/C3XS09
M77)<CUB4_P!*1?CSXWB;_D+JW^];(?Z5PSC;D`FH7Z4+'8G_`)^,K^P\L>GL
M(_<>C+^T/XU3EKZT?ZVB_P!*GC_:5\80C+'3)/K;8_D:\L=N<5"SY&/2I>8X
MI/XV2^'<JEO0C]UOR/7T_:D\4QG][9Z3(/\`KFP_K4R_M8:]'CS=&TM_H[BO
M$WX-0R')%4LTQ:^VQ+A+)G_RX7WO_,]Y3]KG4U'[SPY8-CTNG']*</VO[U#S
MX;M1]+MO\*^?SW%0OUJ_[8QJ7QCCP?DK_P"7/XR_S/H<_MAW0^]X;A_\"S_\
M30O[8LO_`"T\,H3[7?\`]:OG*1N<>E,8\9J%G6-_G#_4K)'I['\9?YGTB?VR
M@OWO##?A>#_"D_X;,B_Z%:0_]O@_PKYHDP>U1D8%4L\QJ^T-\"Y(]J7XO_,^
MFC^V?$O7PK-^%ZO^%-/[:5NO7PI/_P"!J_X5\Q,<FH)#EOI5+/L9_,+_`%"R
M1_\`+I_>_P#,^HC^VQ;#C_A%;G_P-7_"F_\`#;5N.OA2Y_\``U?\*^6W/3BH
MCUH_M[&_S&K\/\C2_A/_`,"9]3G]MZU4\>$[G/\`U^K_`(4P_MP6_P#T*5Q_
MX'+_`/$U\JOG=Q3&;G'%)Y[C?YBH^'N1M?PG_P"!,^JF_;C@'`\(S_C?+_\`
M$TQOVY80./"$WXWJ_P#Q-?*A&<FHW8@&C^W<;_,:KP^R)?\`+I_^!/\`S/JI
MOVZ\#Y/"3CZWP_\`B:A/[=LJC*>$US[WO_V-?*C-R::.GXTGGF-_F-H\`Y!;
M^#_Y-+_,^IW_`&\+P_=\)0?C?-_\35>3]O#4\'9X2L?;=?/_`/$U\O'H:A<X
M%3_;6._Y^?D;1X"R"W\#_P`FE_F?34W[=.ON#Y7A;28SV+74C8_2LV?]N7QD
MY/V71]"B^JNW]:^<CS1]T5+SC&O>HS>/`O#^_P!77WR_S/>+K]M/XB3.3!_8
MUN#_`'+3./S-9ES^V%\39R=FKV4/^Y8)_6O&"<U$>I^M9O,\7_S\9VT^$,CA
MMAH_-7_,]9G_`&J?B=,"6\3.OLEI$/\`V6LVX_:1^)-WS+XLU%>WR!5_D*\W
M;[II@Z&L_KV*>]1_>=4>&\HCMAH?^`Q_R.[N/CO\0KA3O\7ZY@^ESM_D*Q+W
MXD^*]0_X_/$VO29];Z3^A%<^.E1T?6Z\MYL[*>3Y?37N4(K_`+=7^1HR^(]6
MG'[_`%?593_MWDC?S:J<EU/,?WUQ,_\`O2$_UJ*BLW.;=W)G5'"T(JT8)?)?
MY#'5>XR>I)YIK$8XI[=?PJ)NE9)WW.I145H'%`I**.1+5$W%STI0,YYIM(7*
M=.]-R:8XKM_7ZC#D44H.:*@U3[H_9.BBBOU4_B@****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`$Q1M'I2T4;`)@4%0>H%+10`@`'048%+10`FT>E&T>@I:
M*`L)@>E(44G)49]<4ZBG<!GE+Z4OEKC``Q3J*!60P1(!@`8]*J7.B:?>#%W9
M6LW_`%TA5OYBKU%2XI[E1;C\.ASEQ\/_``Y=$^?H6E,O;_1E'\A6-=_!GPA>
M+A]#M8S_`'H\I_(UWE-`]:REAZ4MX)G33QV)I_!4:^;/+;G]GSPBYR+:ZBS_
M`,\KAN/SS6?<_LX>'I`397FIV[>I</\`TKV%D..*3RL]364L!A9K6FCKAGV9
MPTC6E]YX+<_LSO\`-]AUU@.PEM\_R-9UQ^SCKL2;H-0L)LGH59*^C0N.@I&4
MGMGZFL)91A'M$[*?%>;15O:7^1\R3_`CQ/;*?+6RE(Z;)SG]165<_"WQ39C$
MND3RX[Q,&S^5?6`7CD8_&FF(EB<G\ZS>2X9K1M'53XSS*&Z4CY"?P;KT`S+H
M^I(1V^SDU4ETG4K8?Z1IU['CJ6MV']*^R/)QT/--:#<,,J.#UW#-8/(8?SG9
M3XYQ"^*DOO9\6O*T9Q(K(1V8$4T2!NC`_0U]C7'AZQN\FXL;&4GKOMU/]*SK
MCX=>';H$3:+IQSU*Q!?Y5B\AETD=T..X->_1?R:/D9I1G`YJ.0G'6OJV?X.^
M%)E_Y!$"D]U9A_6LBY_9_P#"]PQ*PW,.?[EPU8RR.O;1HZZ?&V"?Q0DON9\Q
M$G/-1N_-?2$_[-N@N#Y%Y?Q9Z?.&_F*R[C]F&V=3]FUNY0]@\*D?H:YIY+BX
MZV3.^CQCE4G[TFO5/]#Y[;Y\GK4+9"GK7MEY^S!K$;?Z#J]C*/\`;C9369-^
MS5XL3)BNM+E]O.9?Z5SO*\6M?9GH0XHRB?\`R]_3\SQ^1CV)J/DCG->FWG[/
MGC.W!Q:6<H_Z9W`_K7/WWP@\96(/F:%=2#/6(JX_0UD\%B%]A_<>A1SW+9Z1
MJQ^]'&,<GDU#)\IK>G\#^([?/GZ%JJ8_Z=6/]*SKG1-1A!\[3[V/'7=;L/Z5
MR3HU$_A9Z-'&X:6U1?>C,=LG%1/4T\,L)_>QR(?]M"/YU5:0,>HX]ZRY7V.Z
M,HR^%H:QXJ`\]:F<C'WA^=0D@'K43:V-X^1#(?FJ-CR!FI9!@9XQ]:A<$X8<
MBH*:&O\`?'IBH2>#FGYZGTJ)SD57*S5/083DG%5V[U.>!4![TK&B?F,DZBH>
MYJ9^2,5`V1R*3T.E(:W6HSZFGGU-1D\4%H9_C43]_K4I.,5#)T_&@N.NQ">I
MI.,4K=3494D\8H-=A,Y'6HGZ4\G:>:8_2@J(8&SI40P5.[&:DW#;BHB.:9K%
MI""HSU/UJ6HS]XT,H:WW33!T-.+'HU(>E""_01>E1T\,!UIE5'<T8448S1BJ
M$-;K^%1-TJ5^#GM49K-;FCV&T48]Q16ES,!UI)!TI1UHD[5$MRX[#****DH_
M9.BBBOU4_BH****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@"+RP?6FO'C&<=:FVCTHP*">5%8H#_#GWI#`K##1QD>XJR44
M]12@8Z4U;JAK0SI]%L;M2MU96DH/9X5;^8K&O/AMX7O<_:_#VE2D]S;@?RKJ
ML48S4N%/^4UC6JQ^&37S9Y[-\#?`TQ8GP[8(6ZA`5_D:SKG]G+P'<@_\2?RV
M/0I.X_K7J>T>E($`/`K*>%P\MX(ZX9KCX?#6DO\`MYGB5Y^R?X*N>8SJMO[1
MW.1^H-9EQ^QYX7F;_1]4UF/CNR-C]*^@<"DVCTKGGEF$DK.FCLI\2YO3^'$2
M^^_YGS;=?L::448VGB+45('`>!#6!>?L;WA#?8/$=N?036Y_I7UEM!ZBF^4G
M]T5E_8N!M\!V0XRSR#NJ_P!Z3/C>Z_8Z\6*#]DU71)U'0DNG]*R9_P!D?Q['
MDQ#2)L?W;K&?S%?<`4+T`%&`:Q>08%N_*>A#Q!SN/VD_D?!$O[,'Q$0';I-O
M)_N7:?XUC:C^S]\0+`'S/#5Z_O$5?^1K]$-H]*;Y29SBLI\/8:6S:.FGXCYI
M%>]"#^37ZGYG7WPT\6V`(O/#>M1^O^B,?Y5D2^&-:@)$NC:LN/6RD_PK]23&
MI&"`133!&>J*?PKGEPU3>TV>A2\4,9'XZ$7\VC\J[C3;V$@2V5XG^_`P_I5*
M821\21NF#_$I%?J\UC;M]Z"(Y]4%4KKPQH]\I%YI>GS`]=]LI_I63X9_EJ'=
M3\5/Y\+]TO\`.+/RG+*<<@$GIFDR",#!_&OT[N_@_P""KYV:Z\+:+(7/)^R*
M,_E6+??LY?#:ZR9?".F`MU*!E_D:SEPQ46L9K\3NI>*F$_Y>4)1]+/\`-H_-
MEAS3).!7Z)3_`+*OPTGZ>'5B_P!R>0?UK,N/V0/AK*S8TV_CS_<O7'\ZR?#F
M*Z-?C_D==/Q4RIZ.G/[E_F?GX?:FDD]J^\KG]BGX?3)B%]<@)[I=YQ^8K)G_
M`&%/",A)M]<U^(=@S1M_[+42X=QB['H4O$W([>]S+_MT^(2^.HIF><U]H7'[
M!>C.Q^Q^)M37C_EI"A_E6;<?L#(0?L_B]U/8/9`_R:L7D>-_E.N'B1D$O^7C
M7_;K/CXG+&@]*^K;C]@/5AG[+XLL&/;S+-Q^H-8=]^PIXSB!%GK.ASD=/OIG
M\Q6;R?&K[!V0X\X?EK]82]4_\CYJ/44E>^W/[$WQ*C)\F/0YL?W;_;G\Q6;)
M^QU\4(_NZ1I[_34$J?[+QD?BIL[J?&.0U%[N*C]]OS/%!2DX%>NW/[)_Q0MQ
MSX<W_P#7*ZC;^M9-W^SA\2[3(D\(ZBX']PHW\C64\)B(O6#.NEQ-E#?NXF'_
M`($CS-FS3:[*Z^#?CFS)^U>$M?7'7;9,W\A6-<^"?$=F<77A_7(B.N^PD']*
MQ>&K+>+/0AFN`G\->#])+_,QL"FGK5J72-2A.)M.U%#_`+5I(/Z5$UK<1_ZR
MVN5_WH6']*E4YIZIFOUJA+X9I_-$0ZT2=J"=IY!4^],DD7CYA^=3)/=Z&D*D
M'HF%%-W`]"#^-%9W7=?>;:=T?LK1117ZL?Q2%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%5T`9FFNQ'0FBBH3U&,W'<*=G
M(YHHH;=Q60Y>E,?@$X&1116BV,[ZE<7#D=14D;EP=V#110_B-JFBT'8']T4_
M:,=!115&$9-O<:P"@$`<TY"3[?2BBCH=$4K7&%R,TF[S`0P&/I114V1"V9$]
MM"Y_>00O_O(#5:30M-G8F;3[%\_WK=#_`$HHK.4(WV!SDEHRO<^"?#T\9$VA
MZ0_?YK*,_P!*R+CX6>#;P$7/A;09/K8Q_P"%%%5&C3DM8K[BUC,3"24:C7HV
L9D_[/OPWO<//X,T$L>I6V"_RHHHK"6%H7^!?<COCFV8**M7G_P"!/_,__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
